Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
The rapid spread and severe impact of the monkeypox outbreak, particularly in Africa, has raised significant concerns globally. This crisis has prompted in vitro diagnostic (IVD) companies around the world to accelerate the development of advanced detection products to tackle this urgent public health issue.
To effectively detect monkeypox, several key methods are employed. Enzyme-Linked Immunosorbent Assay (ELISA) is used to identify IgG and IgM antibodies, which helps in diagnosing current or past infections. Immunohistochemistry (IHC) is another crucial technique used to detect viral antigens in tissue samples. These diagnostic methods are essential for distinguishing monkeypox virus infections from other similar poxviruses, such as those caused by herpesviruses.
Despite the utility of antibody detection methods, the high degree of cross-reactivity among orthopoxviruses poses a significant challenge in achieving specific confirmation of monkeypox. This cross-reactivity can lead to false positives or difficulties in distinguishing between different poxvirus infections. Consequently, the selection of highly specific antigen proteins and antibody combinations is imperative to ensure accurate differentiation and reliable diagnosis of monkeypox. Advanced and precise diagnostic tools are essential for effectively managing and controlling the spread of the virus and addressing this critical public health crisis.
To support IVD companies in meeting the demands of monkeypox detection, Creative Biogene has developed a series of monkeypox virus-related antibodies and recombinant protein products. These products are meticulously developed using the company's established cell expression platform, stable cell line screening platform, gene editing platform, and recombinant protein expression platform, ensuring high quality and cost-effectiveness.
The selection and pairing of antibodies are central to the development of detection kits in methods such as ELISA and immunoblotting. To achieve high sensitivity and specificity in detection, antibodies with high affinity and strong specificity must be selected and validated through pairing experiments to ensure their synergistic effect in detection.
Creative Biogene's paired monoclonal antibodies, including those for A35R, A29L, and M1R, are rigorously validated for superior performance across various applications. These antibodies enhance detection signals and reduce background noise, improving accuracy. For example, our monkeypox A29L antibodies detect at 1-10 pg/ml, while the E8L antibodies achieve around 20 pg/ml sensitivity. All paired antibodies have batch-to-batch variation within ±1%, ensuring consistent and reliable results. These optimized clones meet the high standards of sensitivity and specificity required for advanced kit development.
Figure 1. Colloidal Gold Test Strip Structure Diagram
In immunodetection, quality control antibodies are crucial for consistency and reliability. Creative Biogene provides a range of IgG and IgM antibodies for A29L and A35R, meticulously validated for stability and batch-to-batch consistency. These antibodies remain stable for at least 24 months at -80°C and retain activity for 6 months at -20°C. In ELISA, they show up to 98% batch-to-batch consistency with a CV below 5%. In Western blotting, they exhibit exceptional specificity with cross-reactivity rates below 0.1%. Creative Biogene's quality control antibodies ensure robust support for ELISA and immunoblotting, maintaining high standards and consistency in your experiments.
| Cat. | Product Name |
| MP-AB-001 | Human Anti-Monkeypox A29L mAb (5 high-performance clones) |
| MP-AB-002 | Human Anti-Monkeypox A35R mAb (3 high-performance clones) |
| MP-AB-003 | Human Anti-Monkeypox E8L mAb (3 high-performance clones) |
| MP-AB-004 | Human Anti-Monkeypox M1R mAb (3 high-performance clones) |
| MP-AB-005 | Human Anti-Monkeypox A29L IgG |
| MP-AB-006 | Human Anti-Monkeypox A29L IgM |
| MP-AB-007 | Human Anti-Monkeypox A35R IgG |
| MP-AB-008 | Human Anti-Monkeypox A35R IgM |
| MP-AB-009 | Human Anti-Monkeypox M1R IgG |
| MP-AB-010 | Human Anti-Monkeypox M1R IgM |
By expressing high-quality recombinant proteins, reliable standards and controls can be provided for antigen detection. Creative Biogene offers a variety of monkeypox virus-related recombinant protein products, designed based on the genetic sequences of the monkeypox virus and expressed and purified using the E.coli expression system. These recombinant proteins serve as positive controls in antigen detection, ensuring the reliability and reproducibility of test results.
| Cat. | Product Name |
| MP-RP-001 | Recombinant Monkeypox A29L protein |
| MP-RP-002 | Recombinant Monkeypox A35R protein |
| MP-RP-003 | Recombinant Monkeypox E8L protein |
Advantages of Our Monkeypox Virus Antibodies and Recombinant Proteins
Quality control and standardization are crucial in IVD product development. Creative Biogene incorporates rigorous quality control processes during development to ensure consistency across batches. Our quality control antibodies and recombinant proteins are key in establishing reliable standardization procedures, ensuring consistent performance across different batches of test kits. By offering these high-quality monkeypox virus antibodies and recombinant proteins, Creative Biogene is committed to providing robust technical support to IVD companies worldwide, tackling the challenges of the monkeypox outbreak together.
Copyright © Creative Biogene. All rights reserved.